[1]
|
Berg, K. (1965) A New Serum Type System in Man—The LD System. Vox Sanguinis, 10, 513-527.
https://doi.org/10.1159/000465035
|
[2]
|
Dahlén, G. and Ramberg, U. (1974) Pre-Beta-1 Lipoprotein and Early Detection of Risk Factors for Coronary Heart Disease. Acta Medica Scandinavica, 195, 341-344. https://doi.org/10.1111/j.0954-6820.1974.tb08150.x
|
[3]
|
Clarke, R., Peden, J., Hopewell, J., et al. (2009) Genetic Vari-ants Associated with Lp(a) Lipoprotein Level and Coronary Disease. The New England Journal of Medicine, 361, 2518-2528. https://doi.org/10.1056/NEJMoa0902604
|
[4]
|
Rao, F., Schork, A., Maihofer, A., et al. (2015) Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 35, 1704-1711. https://doi.org/10.1161/ATVBAHA.115.305306
|
[5]
|
Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. https://doi.org/10.1016/j.jacc.2016.11.042
|
[6]
|
Saleheen, D., Haycock, P.C., Zhao, W., et al. (2017) Apolipoprotein(a) Isoform Size, Lipoprotein(a) Concentration, and Coronary Artery Disease: A Mendelian Randomisation Analysis. The Lancet Diabetes & Endocrinology, 5, 524-533. https://doi.org/10.1016/S2213-8587(17)30088-8
|
[7]
|
Libby, P., Buring, J., Badimon, L., et al. (2019) Atherosclerosis. Nature Reviews Disease Primers, 5, Article No. 56.
https://doi.org/10.1038/s41572-019-0106-z
|
[8]
|
Ma, L., Chen, W., Gao, R., et al. (2020) China Cardiovascular Diseases Report 2018: An Updated Summary. Journal of Geriatric Cardiology: JGC, 17, 1-8.
|
[9]
|
Mehta, A., Vasquez, N., Ayers, C.R., et al. (2022) Independent Association of Lipoprotein(a) and Coronary Artery Calcification with Atherosclerotic Cardiovascular Risk. Journal of the American College of Cardiology, 79, 757-768.
https://doi.org/10.1016/j.jacc.2021.11.058
|
[10]
|
Kral, B., Kalyani, R., Yanek, L., et al. (2016) Relation of Plasma Lipopro-tein(a) to Subclinical Coronary Plaque Volumes, Three-Vessel and Left Main Coronary Disease, and Severe Coronary Stenoses in Apparently Healthy African-Americans with a Family History of Early-Onset Coronary Artery Disease. The American Jour-nal of Cardiology, 118, 656-661. https://doi.org/10.1016/j.amjcard.2016.06.020
|
[11]
|
Xia, J., Guo, C., Cao, H., et al. (2022) Impact of Lipoprotein(a) Level on Cardiometabolic Disease in the Chinese Population: The CHCN-BTH Study. Euro-pean Journal of Clinical Investigation, 52, e13689.
https://doi.org/10.1111/eci.13689
|
[12]
|
Kaiser, Y., Daghem, M., Tzolos, E., et al. (2022) Association of Lipoprotein(a) with Atherosclerotic Plaque Progression. Journal of the American College of Cardiology, 79, 223-233. https://doi.org/10.1016/j.jacc.2021.10.044
|
[13]
|
Reyes-Soffer, G., Ginsberg, H. and Ramakrishnan, R. (2017) The Metab-olism of Lipoprotein(a): An Ever-Evolving Story. Journal of Lipid Research, 58, 1756-1764. https://doi.org/10.1194/jlr.R077693
|
[14]
|
Capoulade, R., Chan, K., Yeang, C., et al. (2015) Oxidized Phospholipids, Lipo-protein(a), and Progression of Calcific Aortic Valve Stenosis. Journal of the American College of Cardiology, 66, 1236-1246.
https://doi.org/10.1016/j.jacc.2015.07.020
|
[15]
|
Kamstrup, P.R., Tybjaerg-Hansen, A., Steffensen, R., et al. (2009) Genet-ically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction. JAMA, 301, 2331-2339. https://doi.org/10.1001/jama.2009.801
|
[16]
|
Langsted, A., Kamstrup, P.R. and Nordestgaard, B.G. (2019) High Lipopro-tein(a) and High Risk of Mortality. European Heart Journal, 40, 2760-2770. https://doi.org/10.1093/eurheartj/ehy902
|
[17]
|
Cao, Y., Zhang, H., Jin, J., et al. (2021) Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. Thrombosis and Haemostasis, 121, 1161-1168.
https://doi.org/10.1055/a-1340-2109
|
[18]
|
Langsted, A., Nordestgaard, B.G. and Kamstrup, P.R. (2019) Elevated Lipopro-tein(a) and Risk of Ischemic Stroke. Journal of the American College of Cardiology, 74, 54-66. https://doi.org/10.1016/j.jacc.2019.03.524
|
[19]
|
Capoulade, R., Yeang, C., Chan, K.L., et al. (2018) Association of Mild to Moderate Aortic Valve Stenosis Progression with Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analy-sis of a Randomized Clinical Trial. JAMA Cardiology, 3, 1212-1217. https://doi.org/10.1001/jamacardio.2018.3798
|
[20]
|
Guertin, J., Kaiser, Y., Manikpurage, H., et al. (2021) Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic LPA Gene Expression Levels with Cardi-ovascular Outcomes: Mendelian Randomization and Observational Analyses. Circulation Genomic and Precision Medicine, 14, e003271.
https://doi.org/10.1161/CIRCGEN.120.003271
|
[21]
|
Wong, N., Zhao, Y., Quek, R., et al. (2017) Residual Atherosclerotic Cardiovascular Disease Risk in Statin-Treated Adults: The Multi-Ethnic Study of Atherosclerosis. Journal of Clinical Lipidolo-gy, 11, 1223-1233.
https://doi.org/10.1016/j.jacl.2017.06.015
|
[22]
|
Hardy, J., Niman, S., Goldfaden, R.F., et al. (2022) A Review of the Clin-ical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent. American Journal of Cardiovascular Drugs, 22, 47-54.
https://doi.org/10.1007/s40256-021-00499-1
|
[23]
|
De Boer, L.M., Oorthuys, A.O.J., Wiegman, A., et al. (2021) Statin Therapy and Lipoprotein(a) Levels: A Systematic Review and Meta-Analysis. European Journal of Preventive Cardiology, 29, 779-792.
https://doi.org/10.1016/j.atherosclerosis.2022.06.202
|
[24]
|
Tsimikas, S., Gordts, P., Nora, C., et al. (2020) Statin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. https://doi.org/10.1093/eurheartj/ehz310
|
[25]
|
Yeang, C., Wilkinson, M. and Tsimikas, S. (2016) Lipoprotein(a) and Oxi-dized Phospholipids in Calcific Aortic Valve Stenosis. Current Opinion in Cardiology, 31, 440-450. https://doi.org/10.1097/HCO.0000000000000300
|
[26]
|
Viney, N.J., Van Capelleveen, J.C., Geary, R.S., et al. (2016) An-tisense Oligonucleotides Targeting Apolipoprotein(a) in People with Raised Lipoprotein(a): Two Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Trials. The Lancet (London, England), 388, 2239-2253. https://doi.org/10.1016/S0140-6736(16)31009-1
|
[27]
|
Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020) Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. The New England Journal of Medicine, 382, 244-255.
https://doi.org/10.1056/NEJMoa1905239
|
[28]
|
Koren, M.J., Moriarty, P.M., Baum, S.J., et al. (2022) Preclinical Devel-opment and Phase 1 Trial of a Novel siRNA Targeting Lipoprotein(a). Nature Medicine, 28, 96-103. https://doi.org/10.1038/s41591-021-01634-w
|
[29]
|
Perrot, N., Verbeek, R., Sandhu, M., et al. (2017) Ideal Cardiovascular Health Influences Cardiovascular Disease Risk Associated with High Lipoprotein(a) Levels and Genotype: The EPIC-Norfolk Prospective Population Study. Atherosclerosis, 256, 47-52. https://doi.org/10.1016/j.atherosclerosis.2016.11.010
|
[30]
|
北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.
|